KEGG   DRUG: AdalimumabHelp
Entry
D02597                      Drug                                   

Name
Adalimumab (USAN/INN);
Adalimumab (genetical recombination) (JAN);
Humira (TN)
Product
Class
Other
 DG01936  TNF inhibitor
Remark
Therapeutic category: 3999
ATC code: L04AB04
Product: D02597<JP/US>
Efficacy
Anti-inflammatory, Antirheumatic, Anti-TNF-alpha antibody
  Disease
Rheumatoid arthritis [DS:H00630]
Juvenile idiopathic arthritis [DS:H01672]
Psoriatic arthritis [DS:H01507]
Ankylosing spondylitis [DS:H01674]
Adult Crohn's disease [DS:H00286]
Pediatric Crohn's disease [DS:H00286]
Ulcerative colitis [DS:H01466]
Plaque psoriasis [DS:H01656]
Hidradenitis suppurativa [DS:H00681]
Comment
Monoclonal antibody
Target
TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
  Pathway
hsa04010  MAPK signaling pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04210  Apoptosis
hsa04350  TGF-beta signaling pathway
hsa04380  Osteoclast differentiation
hsa04612  Antigen processing and presentation
hsa04650  Natural killer cell mediated cytotoxicity
hsa05321  Inflammatory bowel disease (IBD)
hsa05323  Rheumatoid arthritis
Interaction
Drug interaction
Structure map
map07050  Antirheumatics - DMARDs and biological agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
     L04AB04 Adalimumab
      D02597  Adalimumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immune Suppressants
   Adalimumab
    D02597  Adalimumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D02597  Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Tumor necrosis factors
    TNF (TNFA, TNFSF2)
     D02597  Adalimumab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D02597
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D02597
BRITE hierarchy
Other DBs
CAS: 331731-18-1
PubChem: 47205810
DrugBank: DB00051
NIKKAJI: J2.104.916F

» Japanese version   » Back

DBGET integrated database retrieval system